

Johan W R Nortier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8401103/publications.pdf>

Version: 2024-02-01

21
papers

855
citations

840776

11
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1456
citing authors

#	ARTICLE	IF	CITATIONS
1	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	1.6	6
2	Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life. <i>Journal of Psychosocial Oncology</i> , 2021, , 1-14.	1.2	0
3	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	12.8	173
4	<p>Illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study</p>. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 67-71.	1.2	6
5	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2019, 21, 97.	5.0	6
6	Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer. <i>Oncologist</i> , 2019, 24, e467-e474.	3.7	26
7	Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 1919-1925.	2.2	11
8	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). <i>Journal of the National Cancer Institute</i> , 2018, 110, 40-48.	6.3	138
9	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67.	2.8	7
10	Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia. <i>European Journal of Oncology Nursing</i> , 2018, 33, 49-55.	2.1	9
11	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 413-420.	2.5	5
12	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1211-1220.	10.7	45
13	Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. <i>Supportive Care in Cancer</i> , 2016, 24, 2735-2741.	2.2	22
14	The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 3.	1.2	16
15	Intensive care admission of cancer patients: a comparative analysis. <i>Cancer Medicine</i> , 2015, 4, 966-976.	2.8	70
16	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. <i>BMC Cancer</i> , 2015, 15, 652.	2.6	170
17	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
18	Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer - TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial. <i>European Journal of Cancer</i> , 2014, 50, 2190-2200.	2.8	67
20	Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2013, 2, 188-200.	2.4	3
21	Routine Monitoring of Quality of Life for Patients with Breast Cancer: An Acceptability and Field Test. <i>Journal of Psychosocial Oncology</i> , 2012, 30, 239-259.	1.2	11